Transfer factor in Hodgkin's disease: a randomized clinical and immunological study

Area of Science:

• Immunology
• Oncology

Background:

• Hodgkin's disease is a cancer of the lymphatic system.
• Patients with Hodgkin's disease often experience compromised immunity and increased susceptibility to infections.
• Transfer factor (TF) is an immunomodulatory agent derived from donor leukocytes.

Purpose of the Study:

• To investigate the efficacy of transfer factor (TF) in enhancing immune response in patients with Hodgkin's disease.
• To determine if TF administration can reduce the incidence of subsequent infections in this patient group.

Main Methods:

• A randomized study was conducted involving 47 patients with Hodgkin's disease undergoing treatment.
• 22 patients received transfer factor (TF) prepared from healthy donor buffy coats.
• 25 patients received a placebo.
• Immunological assessments, including skin test reactivity, were performed.

Main Results:

• Patients receiving TF showed significantly enhanced skin test reactivity compared to the placebo group.
• No significant differences in other immunological assessments were observed between the TF and placebo groups.
• TF did not demonstrate a benefit in preventing infections, including varicella/zoster.

Conclusions:

• Transfer factor (TF) can enhance cellular immunity, as indicated by skin test reactivity, in Hodgkin's disease patients.
• TF did not provide significant immunological benefits beyond skin test enhancement or reduce infection incidence.
• Further research is needed to clarify the role of TF in immunocompromised patients.